HemoSense Raises $7 Million in Private Placement

  
    
  
  
    
      HemoSense, Inc. (AMEX:HEM) today announced that it has closed a 
      private placement in which it sold approximately 1.77 million shares of 
      its common stock at a price of $3.95 per share, raising approximately 
      $7.0 million in gross proceeds from a single institutional investor, New 
      Enterprise Associates (NEA).
    
    
      “We believe that recent developments in our 
      business and industry may provide new opportunities to grow our business 
      and increase market share for INRatio®, our 
      blood coagulation monitoring system,” said Jim 
      Merselis, President and CEO of HemoSense. “Securing 
      these additional funds provides us with flexibility to respond to 
      opportunities on a timely basis. We are very pleased that a 
      sophisticated health care industry investor such as NEA also recognizes 
      the opportunity for HemoSense, and is supporting our efforts.”
    
    
      This press release shall not constitute an offer to sell or the 
      solicitation of an offer to buy any security. The shares and warrants 
      issued in the private placement have not been registered under the 
      Securities Act of 1933 or applicable state securities laws and may not 
      be offered or sold in the United States absent registration under the 
      Securities Act and applicable state securities laws or an applicable 
      exemption from registration requirements.
    
    
      About HemoSense
    
    
      HemoSense develops, manufactures and markets easy-to-use, handheld blood 
      coagulation systems for monitoring patients taking warfarin. The 
      HemoSense INRatio system, used by healthcare professionals and patients 
      themselves, consists of a small monitor and disposable test strips. It 
      provides accurate and convenient measurement of blood clotting time, or 
      PT/INR values. Routine measurements of PT/INR are necessary for the safe 
      and effective management of the patient’s 
      warfarin dosing. INRatio is sold in the United States and 
      internationally. For more information, visit www.hemosense.com.
    
    
      This press release contains forward-looking statements within the 
      meaning of the U.S. Private Securities Litigation Reform Act of 1995. 
      Statements in this press release regarding the Company's business that 
      are not historical facts may be "forward-looking statements" that 
      involve risks and uncertainties. Specifically, the statements regarding 
      the Company’s ability to leverage new 
      opportunities to grow the business and increase the market share for the 
      INRatio system are forward looking statements within the meaning of the 
      Safe Harbor. Forward-looking statements are based on management's 
      current, preliminary, expectations and are subject to risks and 
      uncertainties which may cause the actual results to differ materially 
      from the statements contained herein. Further information on the 
      Company's business and risk factors are detailed in its filings with the 
      Securities and Exchange Commission, including its Form 10-Q for the 
      quarter ended June 30, 2006 filed on August 11, 2006. Undue reliance 
      should not be placed on these forward-looking statements, which speak 
      only as of the date they are made. The Company undertakes no obligation 
      to update publicly any forward-looking statements to reflect new 
      information, events or circumstances after the date they were made, or 
      to reflect the occurrence of unanticipated events.
    
    
      HemoSense® and INRatio® 
      are registered trademarks of HemoSense, Inc.